Uroplasty, Inc. (Uroplasty) is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. Uroplasty offers the Urgent PC system, which is the only United States Food and Drug Administration (FDA) approved minimally invasive, office-based neurostimulation therapy for the treatment of urinary symptoms, urinary urgency, urinary frequency, and urge incontinence often associated with overactive bladder (OAB). Uroplasty also offers Macroplastique, a minimally invasive, implantable soft tissue urethral bulking agent for the treatment of adult female stress urinary incontinence. When Macroplastique is injected into tissue around the urethra, it stabilizes and bulks tissues, providing the surrounding muscles with increased capability to control the release of urine.